Sanofi - American Depositary Shares (NQ:SNY)

39.52 -0.40 (-1.00%)

Delayed Quote Updated: 9:46 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

42 43 Next >

Roblox To Rally Around 34%? Here Are 10 Top Analyst Forecasts For Monday ↗

September 08, 2025

Via Benzinga

This Veeva Systems Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗

September 08, 2025

Via Benzinga

Why Nektar Therapeutics Rippled Higher This Week ↗

September 05, 2025

The company's competitive positioning might be stronger now, after disappointing results from a key rival.

Via The Motley Fool

Topics Intellectual Property

What's Going On With Nektar Therapeutics Stock On Thursday? ↗

September 04, 2025

Nektar Therapeutics stock is trading higher with no news, possibly due to Sanofi's disappointing results.

Via Benzinga

Sanofi’s New Experimental Eczema Drug Meets Goals Of Late-stage Trial, But Wall Street Expected More ↗

September 04, 2025

Via Stocktwits

Novavax CFO Says Sanofi To Cover Majority Of Future Nuvaxovid Study Costs, Retail Urges Partnership Diversification ↗

August 06, 2025

Via Stocktwits

Earnings Scheduled For July 31, 2025 ↗

July 31, 2025

Via Benzinga

Why Is Sanofi Stock Falling Thursday? ↗

September 04, 2025

William Blair notes OX40 antibodies rocatinlimab and amlitelimab trail Dupixent in efficacy, with dosing and side effects shaping their market potential.

Via Benzinga

Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors ↗

September 04, 2025

Sanofi's potential successor to Dupixent, amlitelimab, failed to meet investor expectations in a late-stage trial, raising doubts about its dermatology franchise.

Via Benzinga

Sanofi Tumbles As New Eczema Drug Lags Dupixent's 'Compelling Bar' ↗

September 04, 2025

Can anything beat out Dupixent's "compelling bar" for effectiveness?

Via Investor's Business Daily

C3.ai Posts Downbeat Results, Joins GitLab, Salesforce And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

September 04, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

September 04, 2025

Via Benzinga

Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca Face Renewed Claims Of Conspiring To Restrict 340B Discounts ↗

August 11, 2025

A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict 340B drug discounts for safety-net clinics, sending the case back to...

Via Benzinga

Topics Lawsuit

This Monster Beverage Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday ↗

August 08, 2025

Via Benzinga

RFK Jr. Sued By Eli Lilly, Amgen Over Drug Discount Program ↗

August 06, 2025

Eli Lilly and Amgen are suing HHS over 340B certifications, claiming ineligible clinics cost them millions in lost revenue.

Via Benzinga

Topics Lawsuit

Novavax Ups Outlook, Eyes Stronger Nuvaxovid Sales ↗

August 06, 2025

Novavax beats Q2 expectations with $239 million in revenue, lifts 2025 guidance, and reports profit as costs decline and commercial rights shift to Sanofi.

Via Benzinga

Moderna, Pfizer, Sanofi In Focus As US Winds Down mRNA Vaccine Plans; Retail Turns Bearish On AstraZeneca ↗

August 05, 2025

Via Stocktwits

What's Driving the Market Sentiment Around Sanofi? ↗

August 04, 2025

Via Benzinga

2 Biotech Stocks That Could Soar 29% and 165% According to Wall Street's Top Analysts ↗

August 03, 2025

These biotech businesses look compelling for very different reasons.

Via The Motley Fool

Novo Nordisk's Alhemo Wins FDA Nod, Expanding Subcutaneous Option For Hemophilia Patients ↗

August 01, 2025

FDA approves Novo Nordisk's Alhemo for hemophilia A and B without inhibitors, following strong Phase 3 results showing reduced bleeding episodes.

Via Benzinga

Regeneron's Pipeline Hit By Catalent Delays, But Dupixent Shines ↗

August 01, 2025

Regeneron Q2 revenue rose 4% to $3.68 billion, driven by Dupixent and antibody profits, while FDA delays impacted Eylea HD and odronextamab approvals.

Via Benzinga

Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch ↗

July 31, 2025

Via Stocktwits

Topics Government

Options Corner: Sanofi's Post-Earnings Drama Delivers A Contrarian Discount ↗

July 31, 2025

Although Sanofi delivered an earnings miss which still had encouraging results, SNY stock tanked, offering a potential contrarian discount.

Via Benzinga

Topics Earnings

Sanofi's Q2 Earnings Fall Short On Expectations Despite 21% Jump In Dupixent Sales ↗

July 31, 2025

Sanofi Q2 sales rose 10.1% at constant currency, led by Dupixent and ALTUVIIIO. EPS missed estimates; 2025 sales guidance was revised upward.

Via Benzinga

The Median Retirement Savings for American Households Is $87,000. Here Are 3 Incredible Stocks to Buy Now and Hold for Decades. ↗

July 26, 2025

You should probably be saving more, but even if you can't do that, you can get more out of the money you are able to save.

Via The Motley Fool

Topics Artificial Intelligence Retirement

Eli Lilly's Early Alzheimer's Drug Recommended For Approval By European Drug Regulator's Panel ↗

July 25, 2025

Eli Lilly's donanemab gets CHMP backing for early Alzheimer's in select patients after trials show reduced disease progression and cognitive decline.

Via Benzinga

Novavax Shares Promising Results For Bird Flu Vaccine, Tested In Primates ↗

July 24, 2025

Novavax reports strong immune responses from H5N1 avian flu vaccine candidate, showing promise in single and two-dose preclinical studies.

Via Benzinga

Why Thermo Fischer Stock Is Rising Wednesday ↗

July 23, 2025

Thermo Fisher beat Q2 estimates, raised its 2025 guidance, and announced a CFO transition as easing tariffs support an improved outlook.

Via Benzinga

Topics World Trade

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

July 23, 2025

From Pomerantz LLP

Via GlobeNewswire

Humana Moves To Cut Prior Authorization Delays, Streamline Care Approvals ↗

July 22, 2025

Humana will cut prior authorizations, launch a gold card program, and speed up electronic approvals to improve care access and transparency by 2026.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

42 43 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.